Merck prevails in Singulair patent suit

Merck now has the advantage in its patent tussle over Singulair. A federal judge upheld the drugmaker's patent on the allergy-and-asthma blockbuster yesterday. What's more, the judge ordered a permanent injunction against generics maker Teva Pharmaceutical Industries, which has been fighting to launch its version of the drug, Reuters reports.

Under the judge's order, Teva will be unable to make or sell copycat Singulair until a patent expires in 2012. As you know, Teva applied two years ago for FDA approval for its version of the drug, and Merck sued to protect its product--and its $3 billion or so in annual U.S. sales.

Teva says it's reviewing the latest ruling to determine what to do next. For its part, Merck welcomed the ruling (of course). "The court appropriately ruled that the patent for Singulair in the U.S. is valid," Executive Vice President, Bruce Kuhlik, said in a statement. "We invest heavily in the R&D that is needed to discover innovative medicines like SINGULAIR, and we will vigorously defend our intellectual property rights."

- read the Merck release
- see the news from Reuters
- get more from Haaretz

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.